search
Back to results

Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients

Primary Purpose

Hypertension, Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Nebivolol
Metoprolol ER
HCTZ
Sponsored by
Forest Laboratories
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring nebivolol, Bystolic ™, Hypertension, Diabetes

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

INCLUSION CRITERIA:

  • Male or female, 18-85 years of age
  • Blood pressure in the range of 130 to 179/80 to 109 mmHg
  • Currently using either an ACE inhibitor or an ARB alone or (an ACE inhibitor or an ARB and up to two other drugs for treatment of high blood pressure). (Patients may be on both an ACE inhibitor and ARB, but would need to be taken off one.)
  • Stable medication regimen for high blood pressure for at least one month prior to screening
  • Stable type 2 diabetes mellitus for at least 3 months prior to screening that is controlled by any or all of the following: diet and antidiabetic medications that may include fixed-dose insulin
  • HgbA1c 6.5 to 8.5% (This is measured at the screening visit)

EXCLUSION CRITERIA:

  • Use of any beta blocker within one month prior to screening
  • Use of clonidine within 3 months prior to screening
  • Diagnosis of hyperthyroidism as evidenced by abnormal lab markers
  • Any disorder requiring the intermittent or chronic use of systemic corticosteroids
  • Diagnosis of hyperthyroidism as determined by lab markers done at screening
  • Active liver disease as determined by lab markers
  • Kidney impairment; estimated GFR < 60 mL/min/1.73 m2
  • History of heart attack, clinically significant arrhythmia, unstable angina, coronary angioplasty/bypass surgery, stroke, or TIA in 3 months prior to screening
  • Chronic heart failure
  • Drug or alcohol abuse within 2 years prior to screening
  • History of sensitivity to any beta blocker, HCTZ, sulfa drug, or calcium channel blocker
  • Participation in another research study within 30 days prior to screening

Sites / Locations

  • Forest Investigative Site 15
  • Forest Investigative Site 16
  • Forest Investigative Site 35
  • Forest Investigative Site
  • Forest Investigative Site 54
  • Forest Investigative Site 40
  • Forest Investigative Site
  • Forest Investigative Site
  • Forest Investigative Site 55
  • Forest Investigative Site 11
  • Forest Investigative Site
  • Forest Investigative Site
  • Forest Investigative Site 49
  • Forest Investigative Site 47
  • Forest Investigative Site 61
  • Forest Investigative Site
  • Forest Investigative Site 3
  • Forest Investigative Site 33
  • Forest Investigative Site 36
  • Forest Investigative Site 62
  • Forest Investigative Site 080
  • Forest Investigative Site 59
  • Forest Investigative Site 32
  • Forest Investigative Site 081
  • Forest Investigative Site 2
  • Forest Investigative Site
  • Forest Investigative Site 19
  • Forest Investigative Site 44
  • Forest Investigative Site 5
  • Forest Investigative Site 56
  • Forest Investigative Site 57
  • Forest Investigative Site 39
  • Forest Investigative Site 37
  • Forest Investigative Site
  • Forest Investigative Site 20
  • Forest Investigative Site 50
  • Forest Investigative Site 21
  • Forest Investigative Site
  • Forest Investigative Site
  • Forest Investigative Site
  • Forest Investigative Site
  • Forest Investigative Site 7
  • Forest Investigative Site 45
  • Forest Investigative Site 24
  • Forest Investigative Site 26
  • Forest Investigative Site 18
  • Forest Investigative Site 51
  • Forest Investigative Site 48
  • Forest Investigative Site 12
  • Forest Investigative Site 17
  • Forest Investigative Site 46
  • Forest Investigative Site
  • Forest Investigative Site
  • Forest Investigative Site 4
  • Forest Investigative Site 10
  • Forest Investigative Site 52
  • Forest Investigative Site 28
  • Forest Investigative Site 38
  • Forest Investigative Site 34
  • Forest Investigative Site
  • Forest Investigative Site
  • Forest Investigative Site 31
  • Forest Investigative Site 41
  • Forest Investigative Site 60
  • Forest Investigative Site 29

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

1

2

3

Arm Description

Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration Open-label amlodipine may be given

Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration Open-label amlodipine may be given

HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration Open-label amlodipine may be given

Outcomes

Primary Outcome Measures

Change From Baseline in Mean Glycosylated Hemoglobin (HbA1c) at Week 26
Change from baseline in glycosylated hemoglobin (HbA1c) over 26 weeks, Last Observation Carried Forward.

Secondary Outcome Measures

Change From Baseline in Insulin Resistance Based on Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
Change from Baseline in Insulin Resistance based on homeostasis model assessment of insulin resistance (HOMA-IR) at week 26, Last Observation Carried Forward (LOCF). The HOMA-IR is the the product of the blood Glucose and Insulin levels, divided by a constant. HOMA-IR is expressed as the following: HOMA-IR = fasting serum insulin (μU/ml) × fasting plasma glucose (mmol/l) / 22.5

Full Information

First Posted
August 27, 2008
Last Updated
June 30, 2011
Sponsor
Forest Laboratories
search

1. Study Identification

Unique Protocol Identification Number
NCT00744237
Brief Title
Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients
Official Title
Glycemic Effects of Nebivolol Compared With Metoprolol Extended Release and Compared With Hydrochlorothiazide In Hypertensive Patients With Type 2 Diabetes Mellitus: A Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
June 2011
Overall Recruitment Status
Completed
Study Start Date
August 2008 (undefined)
Primary Completion Date
July 2010 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Forest Laboratories

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will evaluate the effects of nebivolol on glycemic control compared with metoprolol and HCTZ in patients with hypertension and type 2 diabetes mellitus

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Type 2 Diabetes Mellitus
Keywords
nebivolol, Bystolic ™, Hypertension, Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
231 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration Open-label amlodipine may be given
Arm Title
2
Arm Type
Active Comparator
Arm Description
Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration Open-label amlodipine may be given
Arm Title
3
Arm Type
Active Comparator
Arm Description
HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration Open-label amlodipine may be given
Intervention Type
Drug
Intervention Name(s)
Nebivolol
Other Intervention Name(s)
Bystolic (TM)
Intervention Description
Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration
Intervention Type
Drug
Intervention Name(s)
Metoprolol ER
Intervention Description
Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration
Intervention Type
Drug
Intervention Name(s)
HCTZ
Other Intervention Name(s)
Hydrochlorothorazide
Intervention Description
HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration
Primary Outcome Measure Information:
Title
Change From Baseline in Mean Glycosylated Hemoglobin (HbA1c) at Week 26
Description
Change from baseline in glycosylated hemoglobin (HbA1c) over 26 weeks, Last Observation Carried Forward.
Time Frame
visit 5(week 0) and visit 14(week 26)
Secondary Outcome Measure Information:
Title
Change From Baseline in Insulin Resistance Based on Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
Description
Change from Baseline in Insulin Resistance based on homeostasis model assessment of insulin resistance (HOMA-IR) at week 26, Last Observation Carried Forward (LOCF). The HOMA-IR is the the product of the blood Glucose and Insulin levels, divided by a constant. HOMA-IR is expressed as the following: HOMA-IR = fasting serum insulin (μU/ml) × fasting plasma glucose (mmol/l) / 22.5
Time Frame
[visit 5(week 0) and visit 14(week 26)]

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
INCLUSION CRITERIA: Male or female, 18-85 years of age Blood pressure in the range of 130 to 179/80 to 109 mmHg Currently using either an ACE inhibitor or an ARB alone or (an ACE inhibitor or an ARB and up to two other drugs for treatment of high blood pressure). (Patients may be on both an ACE inhibitor and ARB, but would need to be taken off one.) Stable medication regimen for high blood pressure for at least one month prior to screening Stable type 2 diabetes mellitus for at least 3 months prior to screening that is controlled by any or all of the following: diet and antidiabetic medications that may include fixed-dose insulin HgbA1c 6.5 to 8.5% (This is measured at the screening visit) EXCLUSION CRITERIA: Use of any beta blocker within one month prior to screening Use of clonidine within 3 months prior to screening Diagnosis of hyperthyroidism as evidenced by abnormal lab markers Any disorder requiring the intermittent or chronic use of systemic corticosteroids Diagnosis of hyperthyroidism as determined by lab markers done at screening Active liver disease as determined by lab markers Kidney impairment; estimated GFR < 60 mL/min/1.73 m2 History of heart attack, clinically significant arrhythmia, unstable angina, coronary angioplasty/bypass surgery, stroke, or TIA in 3 months prior to screening Chronic heart failure Drug or alcohol abuse within 2 years prior to screening History of sensitivity to any beta blocker, HCTZ, sulfa drug, or calcium channel blocker Participation in another research study within 30 days prior to screening
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John Shea, MS
Organizational Affiliation
Forest Research Institute, a Subsidiary of Forest Laboratories, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Forest Investigative Site 15
City
Athens
State/Province
Alabama
ZIP/Postal Code
35611
Country
United States
Facility Name
Forest Investigative Site 16
City
Huntsville
State/Province
Alabama
ZIP/Postal Code
35801
Country
United States
Facility Name
Forest Investigative Site 35
City
Bell Gardens
State/Province
California
ZIP/Postal Code
90201
Country
United States
Facility Name
Forest Investigative Site
City
Buena Park
State/Province
California
ZIP/Postal Code
90620
Country
United States
Facility Name
Forest Investigative Site 54
City
Chino
State/Province
California
ZIP/Postal Code
91710
Country
United States
Facility Name
Forest Investigative Site 40
City
Fremont
State/Province
California
ZIP/Postal Code
94538
Country
United States
Facility Name
Forest Investigative Site
City
Palm Springs
State/Province
California
ZIP/Postal Code
92262
Country
United States
Facility Name
Forest Investigative Site
City
Pomona
State/Province
California
ZIP/Postal Code
91767
Country
United States
Facility Name
Forest Investigative Site 55
City
Sacramento
State/Province
California
ZIP/Postal Code
95821
Country
United States
Facility Name
Forest Investigative Site 11
City
San Diego
State/Province
California
ZIP/Postal Code
92128
Country
United States
Facility Name
Forest Investigative Site
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Facility Name
Forest Investigative Site
City
Spring Valley
State/Province
California
ZIP/Postal Code
91978
Country
United States
Facility Name
Forest Investigative Site 49
City
Tustin
State/Province
California
ZIP/Postal Code
92780
Country
United States
Facility Name
Forest Investigative Site 47
City
Walnut Creek
State/Province
California
ZIP/Postal Code
94598
Country
United States
Facility Name
Forest Investigative Site 61
City
Golden
State/Province
Colorado
ZIP/Postal Code
80401
Country
United States
Facility Name
Forest Investigative Site
City
Wheat Ridge
State/Province
Colorado
ZIP/Postal Code
80033
Country
United States
Facility Name
Forest Investigative Site 3
City
Daytona Beach
State/Province
Florida
ZIP/Postal Code
32117
Country
United States
Facility Name
Forest Investigative Site 33
City
DeLand
State/Province
Florida
ZIP/Postal Code
32720
Country
United States
Facility Name
Forest Investigative Site 36
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33023
Country
United States
Facility Name
Forest Investigative Site 62
City
Miami
State/Province
Florida
ZIP/Postal Code
33135
Country
United States
Facility Name
Forest Investigative Site 080
City
Miami
State/Province
Florida
ZIP/Postal Code
33169
Country
United States
Facility Name
Forest Investigative Site 59
City
Miami
State/Province
Florida
ZIP/Postal Code
33183
Country
United States
Facility Name
Forest Investigative Site 32
City
Pembroke Pines
State/Province
Florida
ZIP/Postal Code
33024
Country
United States
Facility Name
Forest Investigative Site 081
City
Pembroke Pines
State/Province
Florida
ZIP/Postal Code
33028
Country
United States
Facility Name
Forest Investigative Site 2
City
Tamarac
State/Province
Florida
ZIP/Postal Code
33321
Country
United States
Facility Name
Forest Investigative Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Facility Name
Forest Investigative Site 19
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33401
Country
United States
Facility Name
Forest Investigative Site 44
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30312
Country
United States
Facility Name
Forest Investigative Site 5
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30904
Country
United States
Facility Name
Forest Investigative Site 56
City
Honolulu
State/Province
Hawaii
ZIP/Postal Code
96814
Country
United States
Facility Name
Forest Investigative Site 57
City
Meridian
State/Province
Idaho
ZIP/Postal Code
83646
Country
United States
Facility Name
Forest Investigative Site 39
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60607
Country
United States
Facility Name
Forest Investigative Site 37
City
Wichita
State/Province
Kansas
ZIP/Postal Code
67203
Country
United States
Facility Name
Forest Investigative Site
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21204
Country
United States
Facility Name
Forest Investigative Site 20
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21209
Country
United States
Facility Name
Forest Investigative Site 50
City
Oxon Hill
State/Province
Maryland
ZIP/Postal Code
20745
Country
United States
Facility Name
Forest Investigative Site 21
City
St. Clair Shores
State/Province
Michigan
ZIP/Postal Code
48081
Country
United States
Facility Name
Forest Investigative Site
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64111
Country
United States
Facility Name
Forest Investigative Site
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Forest Investigative Site
City
New Hyde Park
State/Province
New York
ZIP/Postal Code
11042
Country
United States
Facility Name
Forest Investigative Site
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
Forest Investigative Site 7
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28211
Country
United States
Facility Name
Forest Investigative Site 45
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28262
Country
United States
Facility Name
Forest Investigative Site 24
City
Morehead City
State/Province
North Carolina
ZIP/Postal Code
28557
Country
United States
Facility Name
Forest Investigative Site 26
City
Salisbury
State/Province
North Carolina
ZIP/Postal Code
28144
Country
United States
Facility Name
Forest Investigative Site 18
City
Wilmington
State/Province
North Carolina
ZIP/Postal Code
28401
Country
United States
Facility Name
Forest Investigative Site 51
City
Centerville
State/Province
Ohio
ZIP/Postal Code
45459
Country
United States
Facility Name
Forest Investigative Site 48
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45242
Country
United States
Facility Name
Forest Investigative Site 12
City
Wadsworth
State/Province
Ohio
ZIP/Postal Code
44281
Country
United States
Facility Name
Forest Investigative Site 17
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29407
Country
United States
Facility Name
Forest Investigative Site 46
City
Columbia
State/Province
South Carolina
ZIP/Postal Code
29201
Country
United States
Facility Name
Forest Investigative Site
City
North Charleston
State/Province
South Carolina
ZIP/Postal Code
29406
Country
United States
Facility Name
Forest Investigative Site
City
Simpsonville
State/Province
South Carolina
ZIP/Postal Code
29681
Country
United States
Facility Name
Forest Investigative Site 4
City
Sioux Falls
State/Province
South Dakota
ZIP/Postal Code
57104
Country
United States
Facility Name
Forest Investigative Site 10
City
New Tazewell
State/Province
Tennessee
ZIP/Postal Code
37825
Country
United States
Facility Name
Forest Investigative Site 52
City
Corpus Christi
State/Province
Texas
ZIP/Postal Code
78404
Country
United States
Facility Name
Forest Investigative Site 28
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Facility Name
Forest Investigative Site 38
City
Hurst
State/Province
Texas
ZIP/Postal Code
76054
Country
United States
Facility Name
Forest Investigative Site 34
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84102
Country
United States
Facility Name
Forest Investigative Site
City
St. George
State/Province
Utah
ZIP/Postal Code
84790
Country
United States
Facility Name
Forest Investigative Site
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23502
Country
United States
Facility Name
Forest Investigative Site 31
City
Virginia Beach
State/Province
Virginia
ZIP/Postal Code
23452
Country
United States
Facility Name
Forest Investigative Site 41
City
Ponce
ZIP/Postal Code
00717
Country
Puerto Rico
Facility Name
Forest Investigative Site 60
City
Salinas
ZIP/Postal Code
00751
Country
Puerto Rico
Facility Name
Forest Investigative Site 29
City
Santurce
ZIP/Postal Code
00909
Country
Puerto Rico

12. IPD Sharing Statement

Learn more about this trial

Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients

We'll reach out to this number within 24 hrs